Bone-Guard 150 mg (Tablet)

1 tablet kit: ৳ 510.00

Medicine Details

Category Details
Generic Ibandronic acid
Company Incepta pharmaceuticals ltd

Title and Categories

  • Bone-Guard Tablet
  • Medicine
  • Health & Personal Care
  • Osteoporosis Treatment
  • Bisphosphonate Preparations

Dimensions

  • Film-coated tablet: 150 mg
  • Packaging size: 30 tablets per pack

Color Options

  • White tablet
  • Blue packaging

Function

  • Treatment of osteoporosis in women (specially postmenopausal)
  • Prevention of osteoporosis in women (specially postmenopausal)
  • Prevention and treatment of osteoporosis in men
  • Inhibition of bone resorption
  • Increased bone mass
  • Flexible dosing regimens
  • Intermittent treatment with long drug-free intervals
  • Prevents experimentally induced bone destruction
  • Reduces elevated rate of bone turnover
  • Leads to a progressive net gain in bone mass

Material

  • Ibandronic acid
  • Film coating material

Technical Specifications

  • Highly potent bisphosphonate belonging to the nitrogen-containing group of bisphosphonates
  • High affinity for hydroxyapatite
  • Reduces bone resorption with no direct effect on bone formation
  • Reduced bone resorption as reflected in serum and urinary biochemical markers of bone turnover
  • Increased BMD
  • Low plasma protein binding at therapeutic concentrations
  • Eliminated by renal excretion only
  • Does not inhibit the major human hepatic P450 isoenzymes
  • Does not induce the hepatic cytochrome P450 system in rats

Design Elements

  • Plain white tablet with brand name imprint
  • Protective blue packaging
  • Clearly marked dosage instructions on packaging

Usability Features

  • Monthly dosing regimen for convenience
  • Tablets should be swallowed whole with plain water (180 to 240 ml)
  • Patients should not lie down for 60 minutes after taking the tablet
  • Instructions for missed doses
  • Advisory on not chewing or sucking the tablet
  • Requirement for supplemental calcium or vitamin D if dietary intake is inadequate
  • Storage temperature and conditions for product longevity

Interaction

  • Interference with calcium supplements, antacids, and some oral medications containing multivalent cations
  • Absorption interference with some oral medications
  • No interaction potential with tamoxifen or hormone replacement therapy (estrogen)
  • No interaction observed with melphalan/prednisolone
  • Increase in bioavailability with i.v. ranitidine
  • No drug interactions of clinical significance considered likely
  • No inhibition of major human hepatic P450 isoenzymes
  • Low plasma protein binding at therapeutic concentrations

Contraindications

  • Known hypersensitivity to ibandronic acid or any of the excipients
  • Uncorrected hypocalcemia
  • Abnormalities of the esophagus which delay esophageal emptying
  • Inability to stand or sit upright for at least 60 minutes

Side Effects

  • Dyspepsia
  • Nausea
  • Diarrhea
  • Abdominal pain
  • Muscle aches
  • Headaches
  • Dizziness

Pregnancy & Lactation

  • Not for use during pregnancy
  • No clinical experience with pregnant women
  • Not for use during lactation

Precautions & Warnings

  • Treatment of hypocalcemia and other disturbances of bone and mineral metabolism before therapy
  • Caution in patients with active upper gastrointestinal problems
  • Possible esophageal adverse experiences
  • Risk of gastric and duodenal ulcers
  • Osteonecrosis of the jaw (ONJ) risk factors and reporting
  • Effectiveness in patients with renal and hepatic impairment
  • No established safety and efficacy in patients less than 18 years old

Use in Special Populations

  • No dosage adjustment for mild or moderate renal impairment (creatinine clearance ≥30 ml/min)
  • No dosage adjustment for mild or moderate hepatic impairment
  • No dosage adjustment for elderly patients
  • Safety and efficacy not established in patients less than 18 years old

Overdose Effects

  • Possible upper gastrointestinal adverse events
  • Use of milk or antacids to bind Bone-Guard
  • Avoid inducing vomiting
  • Remain fully upright if an overdose occurs

Therapeutic Class

  • Bisphosphonate preparations

Storage Conditions

  • Keep below 30°C temperature
  • Away from light & moisture
  • Keep out of the reach of children

Related Brands